Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 227

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 227
---
 reimburse the Representative
for the fees and expenses of its legal counsel in connection with the offering in an amount not to exceed $125,000, the fees and expenses
related to the use of Ipreo’s book building, prospectus tracking and compliance software for the offering in the amount of $29,500,
up to $15,000 for background checks of our officers and directors, the costs associated with bound volumes of the public offering materials
as well as commemorative mementos and lucite tombstones in an amount not to exceed $3,000, data services and communications expenses
up to $10,000, the actual accountable “road show” expenses up to $10,000 and the costs of market making and trading and clearing
firm settlement expenses up to $30,000; provided however that the aggregate accountable expenses reimbursement will not exceed $175,000.

We expect that the expenses of this offering payable by us, not including
underwriting discounts and commissions, will be approximately $ .

Representative’s Warrants

We have agreed to issue to the Representative, upon the consummation
of this offering, warrants to purchase up to an aggregate amount of Ordinary Shares equal to an aggregate of up to (representing 5.0%
of the Ordinary Shares sold in this offering, including any Ordinary Shares sold upon exercise of the Representative’s over-allotment
option), or the Representative’s Warrants. The Representative’s Warrants are exercisable at a per share price equal to $ (representing
125.0% of the public offering price per share in this offering). The Representative’s Warrants are exercisable at any time and from
time to time, in whole or in part, during the four and one-half (4.5) year period commencing 180 days from the commencement of sales of
the securities in this offering. The Representatives Warrants will provide for registration rights (including a one-time demand registration
right and unlimited piggyback rights) and customary anti-dilution provisions (for stock dividends and splits and recapitalizations) consistent
with FINRA Rule 5110, and further, the number of shares underlying the Representative’s Warrants shall be reduced if necessary to
comply with FINRA rules or regulations.

<div align='center'>137</div>

The Representative’s
Warrants are deemed underwriter compensation by FINRA and are therefore subject to a 180-day lock-up pursuant to FINRA Rule 5110(e)(1)(A).
The Representative